Tenax TherapeuticsTENX
13F holders, Q2 2024 (June 30)11holders +2
4new positions
2sold out
$3.04avg. 13F price*
At the end of Q2 2024, 11 institutions reported holding Tenax Therapeutics Inc. (TENX) in their 13F filings, up 2 from Q1 2024. 4 opened new positions and 2 sold out. The largest holders were Geode Capital Management, LLC ($34K), Qube Research & Technologies Ltd ($13K) and UBS Group AG ($5K).
- Company
- Tenax Therapeutics Inc.
- CUSIP
- 88032L605
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $34K |
| Exits | 2 | $12 |
All 13F filers, Q1 2024 → Q2 2024: 11,598 shares bought and 3 shares sold, net +11,595 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Geode Capital Management, LLC | 0.00% | New | 11,041 | $34K |
| Qube Research & Technologies Ltd | 0.00% | No change | 4,407 | $13K |
| UBS Group AG | 0.00% | Add +8.3% | 1,499 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +79.0% | 961 | $3K |
| CIBC Private Wealth Group LLC | 0.00% | No change | 343 | $1K |
| BlackRock Inc. | 0.00% | No change | 300 | $904 |
| Morgan Stanley | 0.00% | No change | 260 | $784 |
| Bank of America Corp. | 0.00% | New | 16 | $48 |
| Allworth Financial LP | 0.00% | No change | 1 | $4 |
| FMR LLC | 0.00% | New | 1 | $3 |
| Royal Bank of Canada | 0.00% | New | 1 | $0 |
"% of holder's portfolio" is TENX's weight in each manager's 13F, not the share of Tenax Therapeutics Inc. the manager owns.